Anti-CCP autoantibodies are implicated in early bone loss during the preclinical phase of RA and have been reported to independently predict bone erosion in RA patients independent of measures of disease activity such as the disease activity score for RA(DAS28) and inflammation as measured by levels of C-reactive protein (CRP) [121, 123]. Here, CRP is linked to rheumatoid arthritis.